Mutational dynamics between primary and relapse neuroblastomas.
about
The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and BeyondBrigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing.Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations.11q deletion in neuroblastoma: a review of biological and clinical implications.Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastomaIntegrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.Effect of low doses of actinomycin D on neuroblastoma cell linesIntratumoral Heterogeneity of the Epigenome.The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progressionHigh-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells.Neuroblastoma treatment in the post-genomic era.Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma.Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.Genetic discoveries and treatment advances in neuroblastoma.The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosisRetinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.Precision medicine in pediatric oncology: Lessons learned and next steps.TIAM1 variants improve clinical outcome in neuroblastoma.Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding CloneTowards diagnostic application of non-coding RNAs in neuroblastoma.Advances in emerging drugs for the treatment of neuroblastoma.A population genetics perspective on the determinants of intra-tumor heterogeneity.YAP and the Hippo pathway in pediatric cancer.Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma.CFC1 is a cancer stemness-regulating factor in neuroblastoma.Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma.MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities.Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.
P2860
Q26744806-C312DB15-E014-4F80-A7D7-275533F53D77Q27853373-EDAC1C49-1945-467C-B2B0-2E83364F9A5AQ30239861-20E84375-3AF8-4DE3-AA62-90FC15FD2B43Q30391060-1CD98721-E59B-4874-8FA1-6D571ED44B55Q31120836-56658510-348F-432E-B7B5-0B59A521EFC1Q32174267-4339D0E2-9A71-4687-9F7A-CDAF3725CBFCQ33578303-08A636F7-F2AE-428D-94B4-A29C978E33DAQ33677392-E16F9772-B008-4187-9816-C317CDC752BCQ36157472-0CAAA0C4-C830-4DB4-9CCA-5067DF2E1BF6Q36229462-B73D2FDD-2358-4F2D-8C75-D8CC4E819E29Q36423770-58FD4B8D-2E9F-4765-8B77-0ECC36A43717Q36854908-948468DE-66A7-4E84-8EB9-F14063FCE10CQ36916287-5932F179-21CA-47F2-A079-193D17781334Q37225412-FF451B15-2E92-4E4F-BA49-D79414613AF9Q37270959-ACD7956B-BB58-4551-B347-3D0C08F5F73CQ37465234-70BA4702-8547-44C6-BD6F-30DB8A556706Q37633731-D1EA50FF-EA53-4DA7-B3D9-4067501D101DQ37699419-CAA58E22-555D-47FE-B95D-CB288E246492Q37718408-DC571312-E3E0-4A06-9092-70D08EA13EB2Q38261762-6FFD54EA-2584-4A12-8E4B-C1A3ADBCA460Q38294764-F84D37E8-C1C0-4A72-863F-DB1B02EF20A1Q38635452-CA319CF0-D69A-4071-A030-17B771A7F0CEQ38635551-A17E4AB2-2D1D-40E1-AC44-AE9B03FA528CQ38700629-885C4B2A-327A-488E-8C5E-315F14D83CEAQ38716908-A9B30E1C-C346-4874-860C-650E4B4DED94Q38810911-C6AF411E-422F-457B-BB7C-8A544FC7802CQ38830217-E8BA1BFD-EA12-419D-8959-4E410B65263CQ38947597-A2B14910-1014-4390-B84F-60E9AEE3C3F0Q38998623-80122ACF-0716-41BA-9920-FB1B67BC2FDBQ39158415-7846DD2B-C6D2-4824-BDDE-5FAC60DBCCB0Q39169154-DEE95B0A-8E2B-44DF-8281-72C9622FA011Q39374990-D556E11D-FD9D-4A53-B361-823C9B8A9E07Q39552426-52D031EC-AD4F-4FE1-843B-19432A2BA94DQ39649613-70E4A987-BC88-435B-BBEB-CCDF2AB415E7Q41233127-940D55FD-A0A8-4946-A286-FE4CA4726F1DQ41345228-BC8F3AE3-04C0-405D-B025-55630D327644Q41346041-B5FC96E3-C12C-43A9-B3E9-C2F6085C9D0AQ42385390-66847A93-9B1B-4D50-B9D2-C1F000ECD9A7Q42431585-4EF359BB-9B01-4188-99F3-7553F1A42AA5Q42630498-881F8198-0EDF-437D-80A9-C68C9971E586
P2860
Mutational dynamics between primary and relapse neuroblastomas.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Mutational dynamics between primary and relapse neuroblastomas.
@en
type
label
Mutational dynamics between primary and relapse neuroblastomas.
@en
prefLabel
Mutational dynamics between primary and relapse neuroblastomas.
@en
P2093
P2860
P50
P356
P1433
P1476
Mutational dynamics between primary and relapse neuroblastomas
@en
P2093
Andrea Odersky
Angelika Eggert
Anne Engesser
Anton G Henssen
Barbara Hero
Christian Gloeckner
Christoph Plass
Christopher Schröder
Daniela Beisser
Ellen Mahlow
P2860
P2888
P304
P356
10.1038/NG.3349
P407
P50
P577
2015-06-29T00:00:00Z